KAYLA AMRHEIN: Open Payments
NPI 1730727678 · TOWSON, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,589 in 70 payments from 15 companies in 2025. Trend: 2023 $2,208 · 2024 $3,310 · 2025 $1,589
Food & beverage: $1,589
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 26 | $575 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $189 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 8 | $157 |
| Janssen Biotech, Inc. | 8 | $135 |
| GENZYME CORPORATION | 3 | $86 |
| Aimmune Therapeutics, Inc. | 3 | $76 |
| Phathom Pharmaceuticals, Inc. | 3 | $75 |
| Janssen Scientific Affairs, LLC | 1 | $69 |
| Madrigal Pharmaceuticals | 2 | $52 |
| Gilead Sciences, Inc. | 2 | $42 |
Products named: CREON, TREMFYA, SKYRIZI, XIFAXAN, ENTYVIO, RINVOQ, DUPIXENT, ZENPEP.
Industry payments across MD — which companies pay providers there.
